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INTRODUCTION
The significance of human papillomavirus (HPV) 18 genotype 
in treatment outcome is one of the most controversial issues 
regarding HPV-related human tumors [1-7]. In most of the 
studies regarding this subject, low frequency of HPV 18 
infection (around 10% to 20%) often resulted in borderline or 
less than a statistically significant impact on prognosis [1,4,5,7]. 
Likewise, Kim et al. [7] showed a tendency for the HPV 18 
genotype to be associated with poor disease-free survival 
(DFS) and with a trend for poor local control. However, the 
significance of HPV 18 was lost in multivariate analysis in that 
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Objective: To evaluate whether human papillomavirus (HPV) genotype is associated with poor prognosis of uterine cervical 
cancer treated primarily with radiotherapy.
Methods: HPV genotyping was performed in 181 radiotherapy patients using SPF10 polymerase chain reaction and HPV reverse 
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Results: HPV type 18 was associated with poor disease-free survival on univariate analysis but the statistical significance was 
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study.
Because a recent large-scale study showed that HPV 18 is a 
strong prognostic factor for relapse-free survival in patients 
with early-stage cervical cancer treated by surgery [4], the 
authors felt that it was important to clarify that the tumors 
with HPV 18 infection are also associated with poor outcome 
after radiotherapy. If such an association exists, it would 
be necessary to make efforts to develop a new treatment 
method in this subset of patients. 
MATERIALS AND METHODS
1. Study population and treatment
This study was performed under the approval of our Institutio-
nal Review Board, and informed consent was obtained from all 
patients. The patients included 181 consecutive radiotherapy 
patients with International Federation of Gynecology and 
Obstetrics (FIGO) stage IIA–IVB cervical cancer treated between 
July 2003 and December 2008 at the National Cancer Center, 
Korea. Of 181 patients, 167 patients were included in our pre-
vious study [7]. Staging work-up included bimanual physical 
examination, posterior-anterior chest radiography, cystoscopy, 
and rectosigmoidoscopy in all patients. Magnetic resonance 
imaging of the pelvis±abdomen was obtained in 180 patients, 
and either positron emission tomography (PET) scan or PET/
CT scan was obtained in 140 patients. Thirty-seven patients in-
cluded in the previous institutional protocol undertook laparo-
scopic lymph node staging prior to radiotherapy. 
Radiotherapy consisted of whole pelvic external beam 
radiotherapy (EBRT) and high-dose-rate (HDR) brachytherapy. 
Midline block was inserted at 36-45 Gy, giving a whole pelvic 
radiotherapy dose of 45-50.4 Gy. HDR brachytherapy was 
performed at the beginning of midline block with fractional 
doses of 4-5 Gy and 5-7 fractions twice a week. Median 
treatment duration was 58 days (interquartile range, 54 to 
64). Most patients were treated with concomitant weekly 
cisplatin 40 mg/m
2 during EBRT, except the 9 patients of 
stage IVB patients who received concurrent 5-fluorouracil/
cisplatin chemotherapy with extended-field radiotherapy. 
Chemotherapy was not given at all in 19 (10.5%) patients 
because of their advanced age and expected poor compliance 
to concomitant chemoradiotherapy. After the conclusion of 
primary treatment, patients were followed up at 3-month 
intervals in the first 2 years, at 4-month intervals in the third 
year, and every 6 months thereafter. Two patients with 
tumors that showed negative HPV DNA in both HC2 and HPV 
genotyping were excluded from the study due to the lack of 
HPV genotype information. Patients with multiple infections 
including the HPV 18 were grouped as HPV 18 infection.
2. Extraction and amplification of HPV DNA and HPV 
genotyping by LiPA
Genomic DNA was extracted from paraffin-embedded 
tissue sections or frozen tissues using the QIAamp DNA 
mini kit (Qiagen, Hilden, Germany). The SPF10 polymerase 
chain reaction was performed and the amplimers were sub-
sequently analyzed by reverse hybridization on the HPV 
reverse hybridization line probe assay (INNO-LiPA HPV Geno-
typing CE [LiPA]; Innogenetics N.V., Gent, Belgium) under 
the manufacturer’s instructions. LiPA permits the specific 
detection of 16 HPV genotypes, including 14 high-risk HPV (16, 
18, 31, 33, 40, 45, 51, 53, 54, 58, 59, 66, 68, 70) and 2 low-risk 
HPV (HPV 6, 11).
3. Statistical analyses
Demographic and clinical characteristics are presented as 
counts and percentages for categorical variables; median and 
range are supplied for continuous variables. The distributional 
differences between groups were assessed using the 
Pearson chi-square test or Fisher’s exact test. As measures of 
prognostic outcome, DFS and local recurrence-free survival 
were considered. The multivariate Cox proportional hazards 
model was employed to adjust the effects of other potential 
confounding factors such as age, HPV type 18, stage group, 
nodal status, tumor size, histologic grade, histologic type, and 
smoking status. The final multivariate Cox model was chosen 
based on the combination of a stepwise procedure and the 
hierarchical selection method, as well as consideration of the 
clinical or biological importance of the variables in the model. 
A bivariate Cox regression was performed for HPV 18 with 
other parameters to detect the factor(s) which might have 
influenced the prognostic significance of HPV 18. All statistical 
analyses were performed using SAS ver. 9.1 (SAS Inc., Cary, NC, 
USA). Kaplan–Meier curves were generated using STATA ver. 
10 (Stata Co., College Station, TX, USA). All reported p-values 
are two-sided.
RESULTS
1. Treatment outcomes and clinical variables
From the beginning of the observed study period until 
the time of analysis, 54 patients had disease progression, 
including 40 distant metastases and 18 local recurrences. Five 
patients developed both local and distant recurrences. The 
patients were followed up for a median period of 33 months 
(range, 2 to 72 months). The median follow-up for the patients Joo-Young Kim, et al.
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without recurrence was 42 months (range, 6 to 72 months). 
HPV 18 was detected in 20 of the 181 patients (11%) as a single 
(11) or multiple infections (9). Adenocarcinoma (AD) histology 
was 17 with 11 AD and 6 adenosquamous carcinoma (ASC). 
Patients’ characteristics are shown in Table 1 in relation to HPV 
18. 
2. Univariate and multivariate analyses of radiotherapy 
outcome
Both HPV 18 and AD/ASC histology were associated with poor 
DFS in univariate analysis, with hazard ratios of 2.37 and 3.56, 
respectively (Fig. 1, Table 2). Other prognostic parameters for 
DFS included HPV 18, advanced stages, presence of nodal meta-
stasis, poorly-differentiated histologic grade, and tumor size larger 
than 4 cm. In multivariate analysis, advanced stages and AD/
ASC histologic type were significantly related to DFS (Table 2). 
3. HPV 18 and associated clinicopathologic characteristics
HPV 18 was also associated with larger tumor size, posi-
tive nodal status, and also marginally associated with poor 
histologic differentiation (c
2 test, p=0.04, 0.05, 0.06, respec-
tively). Most prominently, tumors with HPV 18 type were 
associated with AD/ASC (92% vs. 8% in squamous cell carci-
noma [SCC], 59% vs. 41% in AD/ASC for non-18 vs. 18 type, 
c
2 test, p=0.001). When bivariate Cox regression analysis was 
performed, the hazard ratio of each parameter remained the 
same regardless of HPV 18 genotype except for the histologic 
type for which the hazard ratio has significantly decreased 
from 2.38 to 1.64 (Table 3). When a combinational group of 
HPV 18 vs. non-HPV 18, and AD/ASC vs. SCC histology was 
made and compared, univariate Cox regression analysis 
revealed that the hazard ratio was increased to 2.1 (95% 
confidence interval [CI], 0.87 to 4.86; p=0.10), 3.67 (95% CI, 1.54 
to 8.74; p=0.003), and 4.05 (95% CI, 1.58 to 10.33; p=0.003), 
for SCC/HPV 18, AD/ASC/non-HPV 18, and AD/ASC/HPV 18, 
respectively (Fig. 2) compared to the risk of SCC/non-HPV 18 
group. Although statistical significance was not shown, there 
was a strong tendency for patients with SCC/HPV 18 infection 
Table 1. HPV 18 and clinicopathologic variables of the patients (n=181)　
Characteristics No. (%) No. of HPV 18 (%) p-value No. of relapse (%)
Event 　 　 　 54 (29.8)
HPV genotype
    Non HPV 18 161 (89) 43 (23.8)
    HPV 18 20 (11) 11 (6.1)
Stage group 　 　 0.12 　
    IIA / IIB 142 (78.5) 15 (75) 　 30 (16.6)
    IIIA / IIIB / IVA   29 (16.0)   2 (10) 　 16 (8.9)
    IVB 10 (5.5)   3 (15) 　 8 (4.4)
Nodal status 　 　 0.04 　
    Negative   75 (41.4)   4 (20) 　 13 (7.2)
    Positive 106 (58.6) 16 (80) 　 42 (22.7)
Histologic type <0.0001
    SCC 164 (90.6) 13 (65) 43 (23.8)
    AD/ASC 12/5 (9.4)  3/4 (35) 6/5 (6.1)
Histologic grade 　 　 0.04 　
    Well/modrate 145 (80.6)    12 (63.2) 　 39 (21.7)
    Poor   35 (19.4)      7 (36.8) 　 15 (8.3)
Tumor size (cm) 0.03
    <4   86 (47.5)   5 (25) 19 (10.5)
    ≥4   95 (52.5) 15 (75) 35 (19.3)
Smoking 　 　 0.89 　
    Non-smoker 151 (83.4) 16 (85) 　 44 (24.3)
    Present/ex smoker   30 (16.6)   3 (15)  　 19 (5.5)
Age Median, 57; Range, 23–80
HPV: human papillomavirus, AD/ASC: adenocarcinoma/adenosquamous carcinoma, SCC: squamous cell carcinoma. HPV 18 and radiotherapy outcome
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to do worse than SCC/HPV non-18 infection. Five of seven 
(71.4%) in 18 type in AD/ASC and 6/10 (60%) in non-18 type in 
AD/ASC relapsed. Four out of 5 ASC showed HPV 18 infection 
and all of them failed locally and distantly. 
DISCUSSION
In the present analysis, we tried to show the effect of HPV 
18 on the outcome of patients with cervical cancer treated 
with concomitant radiochemotherapy. From the results 
of our study, it is hard to conclude that HPV 18 is a strong 
prognosticator on its own, because prognostic significance 
remains stronger for tumor histology than HPV genotype in 
multivariate analysis. Our bivariate analysis showed that the 
effect of HPV 18 on the inferior post-radiotherapy survival was 
negatively influenced by the relationship between HPV 18 
and AD/ASC histology. However, the authors were not able to 
clearly show the interaction of HPV 18 and AD/ASC histology 
because the number of patients with AD/ASC tumors was 
Table 2. Univariate and multivariate analyses for disease-free survival with clinicopathologic prognostic factors
Clinico-pathologid factors Univariate hazard ratio (95% CI) p-value Multivariate hazard ratio (95% CI) p-value
Age* 0.98 (0.96 , 1.00) 0.07 1.00 (0.98, 1.03) 0.89
HPV genotype Non HPV 18 1.00 1.00
HPV 18 2.38 (1.22, 4.61) 0.01 1.05 (0.46, 2.38) 0.91
 Stage IIA/IIB 1.00 1.00
IIIA, IIIB, IVA 3.20 (1.74, 5.9)   0.0002 3.09 (1.65, 5.77) 0.0004
IVB   6.85 (3.09, 15.18) <0.0001   5.55 (2.35, 13.09) <0.0001
Nodal status Negative 1.00 1.00
Positive 2.60 (1.38, 4.86) 0.003 1.76 (0.84, 3.66) 0.13
Histologic grade Well/moderate 1.00 1.00
Poor 1.90 (1.05, 3.46) 0.034 1.52 (0.77, 2.99) 0.22
Histologic type SCC 1.00 1.00
AD/ASC 3.56 (1.83, 6.92)   0.0002 3.29 (1.37, 7.87) 0.008
Tumor size (cm) <4 1.00 1.00
≥4 1.87 (1.07, 3.27) 0.03 1.29 (0.67, 2.49) 0.45
Smoking Non-smoker 1.00 1.00
Ever smoker 1.20 (0.60, 2.38) 0.61 1.51 (0.73, 3.12) 0.27
CI: confidence interval, AD/ASC: adenocarcinoma/adenosquamous carcinoma, SCC: squamous cell carcinoma. 
*5-year increase in age.
Fig. 1. Disease-free survival (DFS) by HPV type (A) and histologic types (B). HPV: human papillomavirus, SCC: squamous cell carcinoma, AD/ASC: 
adenocarcinoma/adenosquamous carcinoma.Joo-Young Kim, et al.
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only 17, and also the prognosis of patients with AD/ASC was 
poor on its own in the absence of HPV 18 infection. The effect 
of HPV 18 is only supported by the poorer survival which was 
observed in SCC/HPV 18 tumors compared to the SCC/non-
HPV 18 tumors. In our study, the poor prognosis of AD/ASC 
tumors is mainly contributed by the poor prognosis of ASC 
tumors. There were 5 patients with ASC tumors and all of the 
patients failed locally or in distant sites; one patient had non-
HPV 18 type and 4 tumors had HPV 18 type. For AD tumors, 
there was 1 failure in 3 HPV 18 types; however, there were also 
5 failures in 9 non-HPV 18 types, making the conclusion that 
the poor prognosis of AD/ASC tumors is entirely due to the 
high proportion of HPV 18. The finding that 4 out of 5 cases of 
ASC showed HPV 18 infection is worth noting because many 
other authors reported that ASC histology is closely associated 
with HPV 18 infection. Fujiwara et al. [2] reported 11 patients 
with ASC who all showed HPV 18 infection in their tumors. 
HPV 18 was frequently associated with AD/ASC in our study 
and also in other studies [1,8-15]. 
We suggest the following common patient characteristics 
which can be observed in both HPV 18 and AD/ASC tumors. 
Firstly, median age of the patients is younger in patients with 
AD/ASC than in patients with SCC tumors [7,16-18], and also 
in patients with HPV 18 tumors than with non-HPV 18 tumors 
[5,19], which may indicate shorter period of carcino  genesis. 
Secondly, viral load is significantly lower in AD/ASC and HPV 
18 tumors compared with SCC and non-HPV 18, respectively. 
In AD/ASC tumors, HPV detection rate ranges from 0-95% and 
33.3-100% respectively and is frequently found to be lower 
than that of SCC [20]. It is not uncommon to find no detectable 
HPV DNA in AD/ASC [21-24]. The lower viral load of AD/ASC 
was also shown in our previous study and in other studies [7,20, 
21]. It is also known that HPV 18 shows significantly low viral 
copy number in many studies [23]. Thirdly, AD of the cervix 
is increasing in incidence worldwide especially in developed 
countries [24,25]. According to a recent report, HPV16 cervical 
tumors are decreasing in incidence while those with HPV 18 do 
not [26]. All of these common clinical characteristics suggest 
a distinct biology of the two minor but important types of 
cervical tumors for which mechanisms of carcinogenesis 
needs to be explicated. Our analysis suggests that there are 
overlapping cancer biology between AD/ASC and HPV 18. In 
HPV 18 cervical cancer, earlier integration of the viral genome 
compared with other types is considered to occur during 
carcinogenesis, which in turn causes greater chromosomal 
instability, higher growth rates, and rapid progression of 
disease [16]. These biological characteristics are likely to cause 
radioresistance, chemoresistance, and finally poor prognosis 
which is supported by many preceding reports [27-38]. Further 
investigation is necessary to reveal the host factors lying 
behind our observation, along with the possible viral factors. 
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